Vikrant Rachakonda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vikrant Rachakonda has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chadi A. Hage
Division of Pulmonology, Allergy, and Critical Care Medicine University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania USA
1 shared publication - Christof Kaltenmeier
Department of Surgery, University of Pittsburgh Medical Center
1 shared publication - Dana Rae Jorgensen
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
1 shared publication - David A. Geller
Department of Surgery, University of Pittsburgh, UPMC Liver Cancer Center, Pittsburgh, PA, USA
1 shared publication - Eric J. Hyzny
Division of Thoracic Surgery Department of Cardiothoracic Surgery University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA
1 shared publication - Ernest G. Chan
Department of Cardiothoracic Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
1 shared publication
Latest Publications
- 12 September 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (10) , e15130
A novel scoring system to predict survival in cirrhotic patients undergoing isolated lung transplantation: The PENS‐CEPT score
Cirrhosis is usually regarded as a contraindication to isolated lung transplantation (ILT). We sought to determine which patients with cirrhosis could safely undergo ILT. Based on a retrospective analysis of patients with cirrhosis who underwent ILT at our center between 2007 and 2020, we developed an exclusionary algorithm (PENS‐CEPT: Pittsburgh ExclusioN Score in Cirrhotics Evaluated for Pulmonary Transplant) to help determine which patients can undergo ILT with minimal incurred risk from their underlying liver disease. The score utilizes a combination of readily available clinical data and the presence (or absence) of spontaneous portosystemic shunts on preoperative cross‐sectional imaging. Sixteen patients underwent ILT with a diagnosis of cirrhosis: nine with cystic fibrosis. On univariate analysis, only our model was able to predict 1 year survival. Of the nine patients that would have been approved using our model, there was only one short term death. Of the seven patients that would have been rejected by the model, all but one died within the first year with six dying of complications from liver failure. We are proposing a simple score utilizing routine clinical parameters and pre‐operative imaging to determine the safety of ILT in cirrhotic patients. Further studies are required to validate this scoring system with the goal of safely increasing the opportunity for cirrhotic patients who would otherwise be rejected for ILT.
- 12 September 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (10) , e15130
A novel scoring system to predict survival in cirrhotic patients undergoing isolated lung transplantation: The PENS‐CEPT score
Cirrhosis is usually regarded as a contraindication to isolated lung transplantation (ILT). We sought to determine which patients with cirrhosis could safely undergo ILT. Based on a retrospective analysis of patients with cirrhosis who underwent ILT at our center between 2007 and 2020, we developed an exclusionary algorithm (PENS‐CEPT: Pittsburgh ExclusioN Score in Cirrhotics Evaluated for Pulmonary Transplant) to help determine which patients can undergo ILT with minimal incurred risk from their underlying liver disease. The score utilizes a combination of readily available clinical data and the presence (or absence) of spontaneous portosystemic shunts on preoperative cross‐sectional imaging. Sixteen patients underwent ILT with a diagnosis of cirrhosis: nine with cystic fibrosis. On univariate analysis, only our model was able to predict 1 year survival. Of the nine patients that would have been approved using our model, there was only one short term death. Of the seven patients that would have been rejected by the model, all but one died within the first year with six dying of complications from liver failure. We are proposing a simple score utilizing routine clinical parameters and pre‐operative imaging to determine the safety of ILT in cirrhotic patients. Further studies are required to validate this scoring system with the goal of safely increasing the opportunity for cirrhotic patients who would otherwise be rejected for ILT.